Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab HYP dose-ranging study in relapsing-remitting multiple sclerosis
ACTRN12606000306516Phase 2Not yet recruiting
- Sponsor
- Biogen
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daclizumab in multiple sclerosis (MS) (4 arms), sponsored by Biogen. Primary endpoint: Total number of gadolinium-enhancing brain lesions over 5 MRI scans. Planned start Jul 2006; status: not yet recruiting.
02
Drugs
daclizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12606000306516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000306516.